Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Abroad (travel likely)RecruitingPHASE2
Conditions
Sjogren's Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NIH Clinical Center Office of Patient Recruitment (OPR) · ccopr@nih.gov · 800-411-1222
Study leads
Blake M Warner, D.D.S.
Principal Investigator
National Institute of Dental and Craniofacial Research (NIDCR)